Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor

Abstract

Provided are novel human-derived antibodies specific for transthyrelin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

Dependencies are inferred from the claim text.